As a result, given that Russo et al. found that many recipients with KIR/HLA incompatibility had GvHD at day 30, it may be inferred that the PTCy therapy specifically eliminates responsive alloreactive KIR2DL NK cells [44]. This evidence concerns the gene KIR3DL1 and graft versus host disease.